Search
forLearn
5 / 801 resultslearn biovolume 128
learn Biopeptide-5
learn Beta Polypeptide
learn oligopeptide-71
Research
5 / 404 results
research Intestinal Permeability Study of Minoxidil: Assessment of Minoxidil as a High Permeability Reference Drug for Biopharmaceutics Classification
Minoxidil works well as a high permeability reference drug for biopharmaceutics classification.
research The Role of Paracellular Transport in the Intestinal Absorption and Biopharmaceutical Characterization of Minoxidil
Minoxidil's absorption is too variable for it to be a reliable reference drug.
research Biopharmaceutical Performance of DiluCap: A Line of Functional Excipients Enhancing Dissolution Profiles of Minoxidil, Finasteride, Melatonin, and Naltrexone.
DiluCap improves how quickly minoxidil and finasteride dissolve and controls the release of melatonin and naltrexone.
research Biopharmaceutical characterization of carbopol gel for the dermal application of melatonin
The gel can effectively deliver melatonin through the skin.
research Biopharmaceutical research on the choice of a non-steroidal anti-inflammatory agent in the development of combination gel for mastopathy therapy
Indometacin was chosen for a gel to help treat mastopathy and prevent breast cancer.
Community Join
5 / 1000+ resultscommunity HMI-115: What We Know So Far. HMI-115 (also known as BAY1158061) is a new pharmaceutical drug developed by a biopharmaceutical company called Bioinvent and licensed by Bayer
HMI-115 is a new drug developed by Bioinvent and licensed by Bayer, with mixed opinions on its potential effectiveness. Some users are skeptical and prefer proven treatments like Minoxidil, finasteride, and RU58841.
community Amplifica Sees Positive Results for Hair Loss Treatment - Results Show 15% increase in 60 days!
Amplifica's new injectable treatment for androgenetic alopecia shows a 15% increase in hair thickness and coarseness in 60 days. The treatment is in early human trials and offers a promising alternative to hormone-related hair loss treatments.
community Amplifica’s AMP-303 Study Unveils New Hope for Hair Loss Treatments
AMP-303, a new injectable treatment for androgenetic alopecia, showed promising results in increasing hair count and density with minimal side effects. The treatment demonstrated significant hair regrowth and durability, offering new hope for those with hair loss.
community Phase II for Technoderma Therepeutic's TDM-105795 set to begin in April tentatively
Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.
community How Veradermics secured a total of $220 million in series B and C financing for oral minoxidil, I will never understand.....
Veradermics' oral minoxidil shows promise for hair regrowth, with some users reporting significant improvements, while Pelage's PP405 results are less convincing and lack transparency. There is skepticism about both treatments' long-term effectiveness and potential side effects.